The landscape of cervical cancer screening in the United States is evolving with the American Cancer Society’s recent update to its recommendations. With an aim to increase accessibility, the guidelines now include self-testing options for human papillomavirus (HPV), the virus linked to nearly all cervical cancer cases. Furthermore, individuals with average risk who receive negative test results at ages 60 and 65 may consider discontinuing screening.
Nevertheless, the guidelines strongly advise that those who do not fulfill these criteria should continue regular screenings until achieving two consecutive negative tests, regardless of age. This is crucial as many cervical cancer cases are detected in older women who have not kept up with their screenings.
Dr. Andrew Wolf, a primary care physician at UVA Health and contributor to the updated recommendations, highlighted the significance of self-testing to diminish screening barriers. He noted that approximately 25% of women in the U.S. are not current with their cervical cancer screenings, a number that can rise to nearly 50% in rural areas.
“Since our guideline update in 2020, there have been a number of studies showing the effectiveness of self-testing in detecting HPV,” Wolf stated. “If we can detect that, then we have a way of finding the risk factor for cervical cancer before cervical cancer starts – actually preventing cancer, not just detecting cancer.”
In May, the Food and Drug Administration approved the country’s first at-home HPV screening device. This device, named the Teal Wand after its creator Teal Health, offers an alternative to the conventional Pap smear, which some patients find uncomfortable. The Teal Wand allows users to collect a vaginal swab sample at home, which is then sent to a lab for testing. It is available in Virginia and over half of the U.S. states. Additionally, various HPV self-tests can be conducted by patients at their healthcare provider’s office, offering options for those who find pelvic exams uncomfortable or face challenges accessing regular healthcare.
Dr. Wolf emphasized that “HPV testing is a more effective way to screen for cervical cancer and pre-cancer than Pap smears.” While Pap smears, developed in the 1940s, involve collecting cervical cells to identify precancerous or cancerous changes, they remain crucial in the screening process. A positive HPV result necessitates follow-up with a Pap smear, also known as cervical cytology. The updated guidelines advise an HPV test by a provider every five years as the preferred method, with options for an HPV self-test or Pap smear every three years, or co-testing with both methods every five years.
Read More Here
